Tel:
Fax:
Email:
Creative Biolabs

Parkinson's Disease Related Research Tools

Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Pathologically, PD is characterized by the presence of abnormal intra-neuronal aggregates of α-synuclein (SNCA). SNCA is central to the pathogenesis of PD, as is highlighted by the fact that rare SNCA mutations, duplications, or triplications cause autosomal dominant familial PD. The etiology of idiopathic PD is multifactorial, likely arising from a combination of polygenic inheritance, environmental exposures, and gene-environment interactions. The current medical management of PD aims at controlling signs and symptoms as long as possible while minimizing adverse effects. Most of them are targeting at supplementation of dopamine to the brain to alleviate motor dysfunction caused by the degeneration of dopaminergic neurons in the nigrostriatal system.

Numerous potential therapies for PD are at various stages of preclinical and clinical testing. These agents target many aspects of PD pathogenesis. Several basic pathophysiological pathways are depicted in Fig.1, including those that lead to Lewy bodies, and those involving inflammatory factors, mitochondrial dysfunction and oxidative stress.

Genetic-based targeted therapies currently being tested in PD patients focus on SNCA, glucocerebrosidase (GBA), and leucine-rich repeat kinase (LRRK2). Multiple lines of evidence support a pivotal role of SNCA in PD pathogenesis. The presence of aggregated α-synuclein in specific brain regions suggests a central role for this protein in sporadic disorder. Heterozygous GBA mutations increase the risk of developing PD and other synucleinopathies. GBA mutations are the most frequent genetic risk factors for PD identified to date, with 7% to 10% of PD patients carrying at least 1 of approximately 300 reported GBA mutations. LRRK2 interacts with many key proteins implicated in PD, suggesting that LRRK2 may be a central player in the pathways underlying disease pathogenesis. The current leading hypothesis shows that increased kinase activity by LRRK2 mutations is responsible for PD. The popular targets in PD researches are listed below:

SNCA GBA PINK1 LRRK2
CYP2D6 PRKN VPS35 PARK7

Creative Biolabs offers comprehensive products as well as high-quality customized services for various targets involved in the signaling pathway for PD research. For any customized services or products, please feel free to contact us for more information.

Parkinson's Disease Assay Service
For Research Use Only. Not For Clinical Use.

Target

Related Products
Loading...
Species:
Human
Relevant Diseases:
Parkinson's Disease
Species:
Human
Relevant Diseases:
Parkinson's Disease
HOT Alpha Synuclein Aggregation Kit [CAT#: NRZP-1122-ZP15]

This kit is designed for an accurate quantitative measurement of alpha synuclein aggregation in brain extracts.

Rabbit Monoclonal Antibody to LRRK2

Host Species:
Rabbit
Species Reactivity:
Mouse; Human
Applications:
ICC; IF; IHC-P; WB
Conjugation:
Unconjugated; APC; PE; HRP; Biotin; FITC

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing

Under standard conditions, at least one siRNA pair achieved an mRNA silencing efficiency exceeding 70%.

Applications:
Gene Silencing
Applications:
Inhibits PINK1 expression to study its role in mitochondrial quality control, mitophagy, and neuronal survival in PD. Facilitates research on PINK1-mediated pathways for neuroprotection. Suitable for in vitro (mitochondrial stress assays) and in vivo (PINK1 mutant mouse models).
Applications:
Modulates DJ-1 expression to investigate its role in oxidative stress response, mitochondrial function, and dopaminergic neuron survival in PD. Enables studies on DJ-1's protective mechanisms against neurodegeneration. Ideal for in vitro (neuroblastoma cell lines) and in vivo (DJ-1 knockout mouse models).
Applications:
Targets SNCA mRNA to decrease α-synuclein aggregation in PD and dementia with Lewy bodies (DLB). Facilitates studies on α-synuclein's role in synaptic toxicity, mitochondrial dysfunction, and neuroinflammation. Suitable for in vitro (dopaminergic neuron cultures) and in vivo (PD mouse models) research.
Applications:
Reduces LRRK2 expression to study its role in neuronal autophagy, mitochondrial dysfunction, and dopaminergic neurodegeneration in Parkinson's disease (PD). Enables preclinical evaluation of LRRK2 inhibition for neuroprotection. Optimized for in vivo PD models (e.g., α-synuclein transgenic mice).
Domperidone [CAT#: NRZP-0323-ZP345]

Relevant Diseases:
Parkinson's Disease
Tangeretin [CAT#: NRZP-0323-ZP300]

Relevant Diseases:
Parkinson's Disease
Relevant Diseases:
Parkinson's Disease
Ropinirole Hydrochloride [CAT#: NRZP-0323-ZP297]

Relevant Diseases:
Parkinson's Disease
Pramipexole Dihydrochloride Monohydrate [CAT#: NRZP-0323-ZP296]

Relevant Diseases:
Parkinson's Disease
Bromocriptine Mesylate [CAT#: NRZP-0323-ZP295]

Relevant Diseases:
Parkinson's Disease
Relevant Diseases:
Parkinson's Disease
Digitonin (Water soluble) [CAT#: NRZP-0323-ZP293]

Relevant Diseases:
Parkinson's Disease
Benserazide Hydrochloride [CAT#: NRZP-0323-ZP292]

Relevant Diseases:
Parkinson's Disease
Zonisamide [CAT#: NRZP-0323-ZP291]

Relevant Diseases:
Epilepsy; Parkinson's Disease
Memantine Hydrochloride [CAT#: NRZP-0323-ZP290]

Relevant Diseases:
Alzheimer's Disease
4-Hydroxy-3-methoxyphenylacetic Acid [CAT#: NRZP-0323-ZP289]

Relevant Diseases:
Parkinson's Disease
3,4-Dihydroxyphenylacetic Acid [CAT#: NRZP-0323-ZP288]

Relevant Diseases:
Parkinson's Disease
Relevant Diseases:
Parkinson's Disease
Product
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
USA

Tel:

Fax:

Email:

UK

Tel:

Email:

Germany

Tel:

Email:

Inquiry Basket
compare

Send inquiry